Subscribe
2022 Guide to Patient Support Services

2021 Novel Oncology Drug Approvals and Their Supportive Patient Programs

BROWSE
2022 Guide to Patient Support Services

At Oncology Practice Management, we believe novel oncology medicines coupled with robust patient support programs drive progress in cancer care.

Innovations in cancer research yielded multiple novel oncology drugs over the past year. Innovations in patient support programs continue to ensure patient access to these medicines as well as access to the resources that keep patients encouraged, empowered, and engaged in their own care.

We are pleased to highlight the 2021 FDA-approved oncology drugs and their accompanying patient support programs in the hope of promoting participation and supporting the best possible outcomes.

TABLE2021 Novel Oncology Drug Approvals and Associated Supportive Patient Programs

Drugs
Companies
Indications
Patient support programs
Drug
Cosela (trilaciclib)
Company
G1 Therapeutics
Indications
To decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/ etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer
Patient support program
Drug
Exkivity (mobocertinib)
Company
Takeda Oncology
Indications
Adult patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Patient support program
Drug
Fotivda (tivozanib)
Company
AVEO Oncology
Indications
Relapsed/refractory advanced renal-cell carcinoma following ≥2 prior systemic therapies
Patient support program
Drug
Jemperli (dostarlimab‑gxly)
Company
GlaxoSmithKline
Indications
Mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen
Patient support program
Drug
Lumakras (sotorasib)
Company
Amgen
Indications
Adult patients with KRAS G12C–mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least 1 prior systemic therapy
Patient support program
Drug
Rybrevant (amivantamab‑vmjw)
Company
Janssen Oncology
Indications
Adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Patient support program
Drug
Rylaze (asparaginase erwinia chrysanthemi (recombinant)‑rywn)
Company
Jazz Pharmaceuticals
Indications
A component of a multiagent chemotherapeutic regimen for acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients ≥1 months who have developed hypersensitivity to E coli–derived asparaginase
Patient support program
Drug
Scemblix (asciminib)
Company
Novartis
Indications
Treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with ≥2 tyrosine kinase inhibitors; treatment of adult patients with Ph+ CML in CP with the T315I mutation
Patient support program
Drug
Tepmetko (tepotinib)
Company
EMD Serono
Indications
Metastatic NSCLC harboring MET exon 14 skipping alterations
Patient support program
Drug
Tivdak (tisotumab vedotin‑tftv)
Company
Seagen
Indications
Adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Patient support program
Drug
Truseltiq (infigratinib)
Company
QED Therapeutics
Indications
Previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, as detected by an FDA-approved test
Patient support program
Drug
Ukoniq (umbralisib)
Company
TG Therapeutics
Indications
Treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least 1 prior anti–CD20-based regimen; treatment of adult patients with relapsed or refractory follicular lymphoma who have received ≥3 prior lines of systemic therapy
Patient support program
Drug
Zynlonta (loncastuximab tesirine‑lpyl)
Company
ADC Therapeutics
Indications
Relapsed or refractory large B-cell lymphoma after ≥2 lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma
Patient support program
NSCLC indicates non–small‑cell lung cancer.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)
SPAM Check, leave blank

CONNECT
Subscribe
Sign Up for Oncology News

Subscribe to recieve the free, monthly OPM print publication and OPM weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.